Hot Features
Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
87.9% of Cadence’s outstanding shares were validly tendered, and subsequent merger has been completed Addition of high-growth OFIRMEV®, a differentiated pain product, will expand...
Stock Price Updates, Appointment, and Financial Results - Analyst Notes on Regeneron, DENTSPLY, AMAG, Cadence, and ArthroCare Editor Note: For more information about this release, please scroll...
Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2013 Financial Results PR Newswire SAN DIEGO, Feb. 28, 2014 SAN DIEGO, Feb. 28, 2014 /PRNewswire/ -- Cadence Pharmaceuticals, Inc...
Lifshitz & Miller Law Firm Announces Investigation of Cadence Pharmaceuticals, Inc., Chindex International, Inc., LCA-Vision, Inc., North Valley Bancorp and Texas Industries, Inc. PR...
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Cadence Pharmaceuticals, Inc. (“Cadence” or the “Company”...
CADENCE PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout - Do you own shares of Cadence Pharmaceuticals, Inc. (NASDAQ GS: CADX)? - Did you...
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Cadence Pharmaceuticals, Inc. (“Cadence” or the “Company”...
Levi & Korsinsky is investigating the Board of Directors of Cadence Pharmaceuticals Inc. (“Cadence” or “the Company”) (NasdaqGS:CADX) for possible breaches of fiduciary duty and other...
Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Cadence Pharmaceuticals, Inc. Juan E. Monteverde...
SHAREHOLDER ALERT: Law Office of Brodsky & Smith, LLC Announces Investigation of Cadence Pharmaceuticals, Inc. - CADX PR Newswire BALA CYNWYD, Pa., Feb. 12, 2014 BALA CYNWYD, Pa., Feb. 12...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
